Use of two recipient lists for adults requiring heart transplantation

Journal of Thoracic and Cardiovascular Surgery

Volumn 125, Issue 1, 2003, Pages 49-59

  Laks, Hillel ^a,b   Marelli, Daniel ^a   Fonarow, Gregg C ^a   Hamilton, Michele A ^a   Ardehali, Abbas ^a   Moriguchi, Jaime D ^a   Bresson, Jessica ^a   Gjertson, David ^a   Kobashigawa, Jon A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; INFLUENZA VACCINE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGE; AGED; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS INFECTION; GRAFT REJECTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HEPATITIS; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; ORGAN DONOR; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; SURVIVAL TIME;

EID: 0037245556     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2003.62     Document Type: Article

References (21)

1. Stevenson LW. When is heart failure a surgical disease? In: Rose EA, Stevenson LW, editors. Management of end-stage heart disease. New York: Lippincott-Raven; 1998. p. 129-46.
2. Annual report of the US Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: transplant data 1989-1998 [monograph online] 2000 Feb 21 [cited 2001 Jul 8]. Available from: URL:http://www.unos.org/Data/anrpt_main.htm
3. Renlund DG, Taylor DO, Kfoury AG, Shaddy RS. New UNOS rules: historical background and implications for transplantation management. J Heart Lung Transplant. 1999;18:1065-70.
4. Borkon AM, Muehlebach GF, Jones PG, Bresnahan DR, Genton RE, Gorton ME, et al. An analysis of the effect of age on survival after heart transplant. J Heart Lung Transplant. 1999;18:668-74.
5. Sweeney MS, Lammermeier DE, Frazier OH, Burnett CM, Haupt HM, Duncan JM. Extension of donor criteria in cardiac transplantation: surgical risk versus supply-side economics. Ann Thorac Surg. 1990;50:7-10.
6. Young JB, Naftel DC, Bourge RC, Kirklin JK, Clemson BS, Porter CB, et al. Matching the heart donor and heart transplant recipient: clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group. J Heart Lung Transplant. 1994;13:353-65.
7. Mudge GH, Goldstein S, Addonizio LJ, Caplan A, Mancini D, Levine TB. et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: recipient guidelines/prioritization. J Am Coll Cardiol. 1993;22:21-31.
8. Laks H, Marelli D, Fazio D, Kobashigawa JA. Expanding the heart donor base. Curr Opin Organ Transplant. 2000;5:134-8.
9. Stein DG, Drinkwater DC, Laks H, Permut LC, Sangwan S, Chait HI, et al. Cardiac preservation in patients undergoing transplantation: a clinical trial comparing University of Wisconsin solution and Stanford solution. J Thorac Cardiovasc Surg. 1991;102:657-65.
10. Leyh RG, Jahnke AW, Kraatz EG, Sievers HH. Cardiovascular dynamics and dimensions after bicaval and standard cardiac transplantation. Ann Thorac Surg. 1995;59:1495-500.
11. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Lung Transplant. 1990;9:587-93.
12. Pflugfelder PW, Thomson D, Singh NR, Menkis AH, McKenzie FN, Kostuk WJ. Cardiac allograft ischemic time: relation to graft survival and cardiac function. Circulation. 1989;80(5 Pt 2):III-116-21.
13. Webster's Ninth New Collegiate Dictionary. Springfield (MA): Merriam-Webster; 1990. p. 72.
14. Ong JP, Barnes DS, Younossi ZM, Gramlich T, Yen-Lieberman B, Goormastic M, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology. 1999;30:1293-48.
15. Jeevanandam V, Furukawa S, Prendergast TW, Todd B, Isen HJ, McClurken JB. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg. 1996;62:1268-75.
16. Young JB. Age before beauty: the use of "older" donor hearts for cardiac transplantation. J Heart Lung Transplant. 1999;18:488-91.
17. Marelli D, Laks H, Fazio D, Sadeghi A, Ardehali A, Moriguchi J, et al. The use of marginal donor hearts (abstract). J Heart Lung Transplant. 2000;19:76.
18. Tsai FC, Marelli D, Bresson J, Gjerston D, Kerman R, Patel J, et al. Use of hearts transplanted from donors with atraumatic intracranial bleeds. J Heart Lung Transplant. 2002;21:623-8.
19. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-86.
20. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, Boehmer JP, Brozena SC, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17:744-53.
21. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-7.